Biodexa shares surge 57.70% intraday as it launches global early/patient-specific access program for eRapa with Tanner Pharma for FAP patients.

Biodexa surged 57.70% intraday, driven by its announcement with Tanner Pharma to launch the eRapa global early/patient-specific access program, providing FAP patients access to the investigational oral rapamycin capsule. Biodexa is a clinical-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal cancers, with eRapa as its core pipeline product.